Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
Clinical trial NCT03205345 · UNKNOWN
Trial details
- NCT number
- NCT03205345
- Sponsor
- Conatus Pharmaceuticals Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-28
- Primary completion
- 2019-08-01
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.